Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment

被引：0
|
作者：
Wang, Jaw-Yuan
Tsai, Hsiang-Lin
Sung, Yung-Chuan
机构：
[1] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung, Taiwan
[3] Cathay Gen Hosp, Div Hematol Oncol, Dept Internal Med, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
208
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Impact of the mutation locus in KRAS codon-12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer (mCRC) receiving cetuximab-based first-line therapy
    Modest, D. P.
    Stintzing, S.
    Jung, A.
    Laubender, R. P.
    Giessen, C.
    Schulz, C.
    Moosmann, N.
    Haas, M.
    Neumann, J.
    Boeck, S.
    Kirchner, T.
    Heinemann, V.
    ONKOLOGIE, 2011, 34 : 208 - 208
  • [42] The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
    Hsiang-Lin Tsai
    Chun-Chi Lin
    Yung-Chung Sung
    Shang-Hung Chen
    Li-Tzong Chen
    Jeng-Kai Jiang
    Jaw-Yuan Wang
    British Journal of Cancer, 2023, 129 : 947 - 955
  • [43] CIGARETTES SMOKING HABIT MAY INDUCE A REDUCED EFFICACY OF CETUXIMAB-BASED TREATMENT IN ADVANCED COLORECTAL CANCER PATIENTS
    Vincenzi, B.
    Santini, D.
    Loupakis, F.
    Llimpe, F. L. Rojas
    Addeo, R.
    Del Prete, S.
    Graziano, F.
    Pinto, C.
    Falcone, A.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 141 - 141
  • [44] Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review
    Wei, Li
    Lin, Zexiao
    Xie, Sidong
    Ruan, Danyun
    Jiang, Wen
    Cui, Yueli
    Liu, Sisi
    Wang, Tiantian
    Chen, Zhanhong
    Lin, Qu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
    Vincenzi, Bruno
    Santini, Daniele
    Loupakis, Fotios
    Addeo, Raffaele
    Llimpe, Fabiola L. Rojas
    Baldi, Giacomo Giulio
    Di Fabio, Francesca
    Del Prete, Salvatore
    Pinto, Carmine
    Falcone, Alfredo
    Tonini, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (08) : 945 - 949
  • [46] Results of a german noninterventional study (NIS) of cetuximab-based therapy in pretreated-patients (pts) with metastatic colorectal cancer (mCRC).
    Jehn, C.
    Stenzel, K.
    Boening, L.
    Kroening, H.
    Possinger, K.
    Lueftner, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Spectrum of RAS Mutations in 946 Korean Patients with Metastatic Colorectal Cancer
    Han, S.
    Hong, S.
    Lim, H.
    Hwang, S.
    Lee, K.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (02): : S28 - S28
  • [48] Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
    Johannes Schöche
    Dora Niedersüß-Beke
    memo - Magazine of European Medical Oncology, 2022, 15 : 39 - 44
  • [49] Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
    Schoeche, Johannes
    Niedersuess-Beke, Dora
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (01) : 39 - 44
  • [50] A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study
    Jiang, Tao
    Chen, Hao
    Wang, Xinli
    Lin, Fangyu
    Wang, Han
    Liu, Jialin
    Lin, Xiaoyan
    FRONTIERS IN ONCOLOGY, 2024, 14
12345